CIMplicity® Savings Program Information for Specialty Pharmacies

Specialty pharmacies can help eligible,* commercially insured patients save on the cost of CIMZIA (certolizumab pegol) throughout treatment

- A **simplified process** is now in place that will enable specialty pharmacies to enroll eligible patients in the CIMplicity Savings program prior to first dispense
- Enrolled patients could pay as little as **$0 per dose** for their medication

Savings are only a part of the benefits offered to CIMZIA patients. **Be sure to tell patients to register at CIMZIA.com to access the full suite of services and resources available to help them successfully manage their condition.**

Eligible* patients can be enrolled in the Savings program in a few simple steps:

STEP 1:

Visit **UCBSavings.com** to begin process

STEP 2:

Complete all **patient eligibility questions as required.** Click **"Create Savings Card"** to download a unique patient CIMplicity savings card

STEP 3:

Utilize information from CIMplicity savings card (BIN, PCN) as the secondary insurance when processing the CIMZIA patient claim



*Certain restrictions apply. Please see full Eligibility Criteria on page 3. This offer is not available for patients eligible for Medicare, Medicaid, or any other form of government insurance coverage.

Please note that card can be saved as a PDF to attach to patient file if desired.

IMPORTANT SAFETY INFORMATION

Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member.

Please see additional Important Safety Information on page 4, refer to accompanying full Prescribing Information, and visit www.CIMZIAhcp.com.

CIMZIA is a tumor necrosis factor (TNF) blocker indicated for:

- Reducing signs and symptoms of **CROHN'S DISEASE (CD)** and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
- Treatment of adults with moderately to severely active **RHEUMATOID ARTHRITIS (RA)**
- Treatment of active **POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA)** in patients 2 years of age and older
- Treatment of adult patients with active **PSORIATIC ARTHRITIS (PsA)**
- Treatment of adults with active **ANKYLOSING SPONDYLITIS (AS)**
- Treatment of adults with active **NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (nr-axSpA)** with objective signs of inflammation
- Treatment of adult patients with moderate-to-severe **PLAQUE PSORIASIS (PSO)** who are candidates for systemic therapy or phototherapy

CIMplicity® Savings Program FAQs for Specialty Pharmacy

1. What do I need to tell a new commercial patient about the CIMplicity Savings program?
The CIMplicity Savings program* offers financial support for eligible CIMZIA patients. Restrictions and maximum limits apply. Direct patients to CIMZIA.com for full eligibility criteria.

2. How does a specialty pharmacy enroll an eligible patient in the CIMplicity Savings program?
Specialty pharmacies can now enroll eligible patients in the CIMplicity Savings program by visiting **UCBSavings.com**. This microsite will generate a **Virtual Coordination of Benefits (COB) card**.

3. How long does the enrollment process take?
If a specialty pharmacy enrolls an eligible patient in the **CIMplicity Savings program,** the enrollment is **instantaneous** and the information will be used as secondary insurance when processing the CIMZIA patient claim.

4. What can the patient expect after they are enrolled by the specialty pharmacy?
Once a specialty pharmacy enrolls a patient in the CIMplicity Savings program, a savings card PDF will be generated that can be downloaded and saved to the patient's chart. The specialty pharmacy could also send the PDF to the patient if desired.

5. What is the process for obtaining savings for refills?
For patients enrolled in the **CIMplicity Savings program** via the specialty pharmacy, the specialty pharmacy will process the savings card as secondary insurance for refills.

6. How often will the specialty pharmacy have to pull a new card for the patient?
The website indicates an end-of-year expiration date, and the patient will need to be re-enrolled each year.

7. Are there any other ways to enroll in the CIMplicity Savings program?
Patients will still be able to self-enroll. Please instruct patients to **visit CIMZIA.com/join-cimplicity.** Patients should have their insurance cards available. *Note: The CIMZIA Savings program hours of operation are Monday through Friday, 8:00 AM to 8:00 PM ET.*

Continued on next page.

8. If a patient has already self-enrolled in the program, should the specialty pharmacy enroll the patient via UCBSavings.com?

If the patient has already self-enrolled or was enrolled via CIMplicity, the specialty pharmacy should use the information provided by the patient when adjudicating the patient's claim. Specialty pharmacies can enroll eligible patients who don't already have a savings card in the CIMplicity Savings program by **visiting UCBSavings.com. Note: All CIMplicity Savings cards associated with the patient will be used to calculate the maximum benefit for the patient.**

9. The patient was shipped CIMZIA prior to enrollment. Are they still eligible for the program?

No. Patients must be enrolled in the Savings program **prior to a shipment** of CIMZIA in order to be eligible for the savings.

10. If a patient has Medicare for their medical insurance but their prescription insurance is through a commercial payer (e.g., Federal Employee Health Plan), are they eligible for the savings program?

If a patient has commercial prescription insurance, they are eligible for the savings program, subject to the other eligibility criteria for the program. The savings program is not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law.

11. Can the CIMplicity Savings program be applied to offset costs incurred by the patient for CIMZIA treatment administered in the office?

Medication shipped from a specialty pharmacy to the patient's home or provider's office will continue to use the current savings program. For CIMZIA medication that is bought by the provider and administered to the patient, patients may be eligible to receive reimbursement for out-of-pocket costs incurred through the CIMplicity Administration Savings program†, a separate savings program in which the office staff can assist the patient to enroll.

12. What if a patient doesn't have insurance?

If a patient does not have insurance, other financial assistance may be available. Have the patient call **UCBCares® at 1-844-599-CARE (2273)** for more information.

> For additional questions related to the program, please call **1-877-705-4119** toll free, Monday through Friday from 8:00 am – 8:00 pm ET.

***CIMplicity® Savings Program**

CIMplicity® Savings (the "Program") provides CIMZIA® (certolizumab pegol) Prefilled Syringe or Lyophilized Powder to eligible patients for as little as $0 per dose. Eligible patients must have commercial insurance coverage and a valid prescription for CIMZIA Prefilled Syringe or Lyophilized Powder consistent with FDA-approved product labeling. The Program is not valid (1) for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded healthcare programs (including but not limited to any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient's commercial insurance plan reimburses for the entire cost of the drug, (3) for uninsured or cash-paying patients, (4) where the product is not covered by patient's insurance, or (5) where otherwise prohibited by law. Product shall be dispensed pursuant to Program rules and federal and state laws. The value of the Program is exclusively for the benefit of patients and is intended to be credited in full toward patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance and deductibles. Patient may not seek reimbursement for the value received from this Program from other parties, including any health insurance program or plan, government healthcare program, flexible spending account, or healthcare savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the U.S. and Puerto Rico. This Program is not health insurance. Proof of purchase may be required. This Program is not transferrable and cannot be combined with any other savings, free trial, or similar offer. UCB, Inc. reserves the right to amend or end this Program at any time without notice. Subject to the prior sentence, this Program expires at 11:59 p.m. on December 31. Patients that meet the above requirements may re-enroll in the Program each year.

†Eligible, commercially insured patients with approved coverage may receive reimbursement for costs incurred for in-office administration of CIMZIA Lyophilized Powder, subject to an annual cap and submission of an Explanation of Benefits (EOB) form to CIMplicity. View complete eligibility requirements and terms at cimzia.com/cimplicity-program.

Please see Important Safety Information on page 4, refer to accompanying full Prescribing Information, and visit CIMZIAhcp.com.

cimzia® (certolizumab pegol)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.

SERIOUS INFECTIONS
Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue CIMZIA if a patient develops a serious infection or sepsis.

Reported infections include:

Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CIMZIA use and during therapy. Initiate treatment for latent TB prior to CIMZIA use.

- **Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.**
- **Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.**

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: with chronic or recurrent infection; who have been exposed to TB; with a history of opportunistic infection; who resided in or traveled in regions where mycoses are endemic; with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

- Do not start CIMZIA during an active infection, including localized infections.
- Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
- If an infection develops, monitor carefully and initiate appropriate therapy

MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. Consider the risks and benefits of CIMZIA treatment prior to initiating or continuing therapy in a patient with known malignancy.

- In clinical trials, more cases of malignancies were observed among CIMZIA treated patients compared to control patients.
- In CIMZIA clinical trials, there was an approximately 2-fold higher rate of lymphoma than expected in the general U.S. population. Patients with rheumatoid arthritis, particularly those with highly active disease, are at a higher risk of lymphoma than the general population.
- Malignancies, some fatal, have been reported among children, adolescents, and young adults being treated with TNF blockers. Approximately half of the cases were lymphoma, while the rest were other types of malignancies, including rare types associated with immunosuppression and malignancies not usually seen in this patient population.
- Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including CIMZIA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis, and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treating with CIMZIA in these patient types.
- Cases of acute and chronic leukemia were reported with TNF blocker use.

HEART FAILURE
- Worsening and new onset congestive heart failure (CHF) have been reported with TNF blockers. Exercise caution and monitor carefully.

HYPERSENSITIVITY
Angioedema, anaphylaxis, dyspnea, hypotension, rash, serum sickness, and urticaria have been reported following CIMZIA administration. If a serious allergic reaction occurs, stop CIMZIA and institute appropriate therapy. The needle shield inside the removable cap of the CIMZIA prefilled syringe contains a derivative of natural rubber latex that may cause an allergic reaction in individuals sensitive to latex.

HEPATITIS B VIRUS REACTIVATION
- Use of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.
- Test patients for HBV infection before initiating treatment with CIMZIA.
- Exercise caution in patients who are carriers of HBV and monitor them before and during CIMZIA treatment.
- Discontinue CIMZIA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming CIMZIA after HBV treatment.

NEUROLOGIC REACTIONS
- TNF blockers, including CIMZIA, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, seizure disorder, optic neuritis, peripheral neuropathy, and Guillain-Barré syndrome.

HEMATOLOGIC REACTIONS
- Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with CIMZIA.
- Consider stopping CIMZIA if significant hematologic abnormalities occur.

DRUG INTERACTIONS
- Do not use CIMZIA in combination with other biological DMARDS.

AUTOIMMUNITY
- Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS
- Avoid use of live vaccines during or immediately prior to initiating CIMZIA. Update immunizations in agreement with current immunization guidelines prior to initiating CIMZIA therapy.

ADVERSE REACTIONS
- The most common adverse reactions in CIMZIA clinical trials (≥8%) were upper respiratory infections (18%), rash (9%), and urinary tract infections (8%).

Please refer to accompanying full Prescribing Information, and visit CIMZIAhcp.com.

cimzia® (certolizumab pegol)